CA2709960A1 - Chemically modified factor ix - Google Patents

Chemically modified factor ix Download PDF

Info

Publication number: CA2709960A1
Authority: CA; Canada
Prior art keywords: fix; ser; water; thr; region
Prior art date: 2007-12-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2709960A

Other languages

English (en)

French (fr)

Inventor

Peter Turecek

Friedrich Scheiflinger

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Baxter Healthcare SA

Baxter International Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-27

Filing date

2008-12-19

Publication date

2009-07-09

2008-12-19 Application filed by Individual filed Critical Individual

2009-07-09 Publication of CA2709960A1 publication Critical patent/CA2709960A1/en

Status Abandoned legal-status Critical Current

Links

229960004222 factor ix Drugs 0.000 title claims description 270
229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 33
101800001401 Activation peptide Proteins 0.000 claims abstract description 10
102400000069 Activation peptide Human genes 0.000 claims abstract description 10
108010076282 Factor IX Proteins 0.000 claims description 280
102100022641 Coagulation factor IX Human genes 0.000 claims description 278
230000000694 effects Effects 0.000 claims description 40
238000000034 method Methods 0.000 claims description 38
239000002202 Polyethylene glycol Substances 0.000 claims description 35
229920001223 polyethylene glycol Polymers 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 29
229920000642 polymer Polymers 0.000 claims description 28
229920001612 Hydroxyethyl starch Polymers 0.000 claims description 22
229940050526 hydroxyethylstarch Drugs 0.000 claims description 22
208000031169 hemorrhagic disease Diseases 0.000 claims description 18
238000002360 preparation method Methods 0.000 claims description 16
150000001720 carbohydrates Chemical class 0.000 claims description 15
230000008878 coupling Effects 0.000 claims description 15
238000010168 coupling process Methods 0.000 claims description 15
238000005859 coupling reaction Methods 0.000 claims description 15
208000009429 hemophilia B Diseases 0.000 claims description 13
239000008194 pharmaceutical composition Substances 0.000 claims description 13
229920002307 Dextran Polymers 0.000 claims description 10
235000014633 carbohydrates Nutrition 0.000 claims description 9
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 8
150000001413 amino acids Chemical group 0.000 claims description 8
229940024606 amino acid Drugs 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
229960002885 histidine Drugs 0.000 claims description 5
239000004471 Glycine Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
229940068968 polysorbate 80 Drugs 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 2
229920000136 polysorbate Polymers 0.000 claims description 2
229950008882 polysorbate Drugs 0.000 claims description 2
229920000053 polysorbate 80 Polymers 0.000 claims description 2
210000004027 cell Anatomy 0.000 description 28
108090000623 proteins and genes Proteins 0.000 description 26
102000004169 proteins and genes Human genes 0.000 description 20
241001465754 Metazoa Species 0.000 description 16
238000003556 assay Methods 0.000 description 12
238000001727 in vivo Methods 0.000 description 12
210000002381 plasma Anatomy 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
210000004369 blood Anatomy 0.000 description 11
239000008280 blood Substances 0.000 description 11
239000003814 drug Substances 0.000 description 11
238000011084 recovery Methods 0.000 description 11
208000032843 Hemorrhage Diseases 0.000 description 10
108020004707 nucleic acids Proteins 0.000 description 10
102000039446 nucleic acids Human genes 0.000 description 10
150000007523 nucleic acids Chemical class 0.000 description 10
230000006320 pegylation Effects 0.000 description 10
239000000243 solution Substances 0.000 description 10
108010048049 Factor IXa Proteins 0.000 description 9
230000027455 binding Effects 0.000 description 9
238000009739 binding Methods 0.000 description 9
208000034158 bleeding Diseases 0.000 description 9
231100000319 bleeding Toxicity 0.000 description 9
230000000740 bleeding effect Effects 0.000 description 9
238000009472 formulation Methods 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
238000006467 substitution reaction Methods 0.000 description 9
238000011282 treatment Methods 0.000 description 9
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
229930006000 Sucrose Natural products 0.000 description 7
239000000872 buffer Substances 0.000 description 7
230000035602 clotting Effects 0.000 description 7
229940079593 drug Drugs 0.000 description 7
230000004481 post-translational protein modification Effects 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
239000005720 sucrose Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
206010053567 Coagulopathies Diseases 0.000 description 6
108010074860 Factor Xa Proteins 0.000 description 6
238000007385 chemical modification Methods 0.000 description 6
230000007812 deficiency Effects 0.000 description 6
125000005647 linker group Chemical group 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
238000007792 addition Methods 0.000 description 5
230000037396 body weight Effects 0.000 description 5
230000002950 deficient Effects 0.000 description 5
-1 hydroxyethyl groups Chemical group 0.000 description 5
230000003647 oxidation Effects 0.000 description 5
238000007254 oxidation reaction Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
230000004988 N-glycosylation Effects 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
230000004913 activation Effects 0.000 description 4
238000001994 activation Methods 0.000 description 4
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000008103 glucose Substances 0.000 description 4
230000013595 glycosylation Effects 0.000 description 4
238000006206 glycosylation reaction Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
150000003904 phospholipids Chemical class 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
230000019635 sulfation Effects 0.000 description 4
238000005670 sulfation reaction Methods 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
241000282412 Homo Species 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229940031422 benefix Drugs 0.000 description 3
229960005069 calcium Drugs 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
239000003593 chromogenic compound Substances 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
235000008504 concentrate Nutrition 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000012537 formulation buffer Substances 0.000 description 3
230000007849 functional defect Effects 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
229960001855 mannitol Drugs 0.000 description 3
239000012528 membrane Chemical group 0.000 description 3
229940067631 phospholipid Drugs 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
125000005629 sialic acid group Chemical group 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000011287 therapeutic dose Methods 0.000 description 3
238000001890 transfection Methods 0.000 description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010014173 Factor X Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
108010056902 Mononine Proteins 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108091005461 Nucleic proteins Proteins 0.000 description 2
239000012506 Sephacryl® Substances 0.000 description 2
108010022999 Serine Proteases Proteins 0.000 description 2
102000012479 Serine Proteases Human genes 0.000 description 2
108010000499 Thromboplastin Proteins 0.000 description 2
102000002262 Thromboplastin Human genes 0.000 description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
125000003172 aldehyde group Chemical group 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
230000003024 amidolytic effect Effects 0.000 description 2
238000005571 anion exchange chromatography Methods 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
150000004652 butanoic acids Chemical class 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000004087 circulation Effects 0.000 description 2
229940105774 coagulation factor ix Drugs 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
230000009395 genetic defect Effects 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
230000028993 immune response Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000002955 isolation Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000003550 marker Substances 0.000 description 2
229940090053 mononine Drugs 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000003058 plasma substitute Substances 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
150000004672 propanoic acids Chemical class 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
238000001542 size-exclusion chromatography Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000003151 transfection method Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
229920003169 water-soluble polymer Polymers 0.000 description 2
ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
BTBWSRPRAGXJJV-UHFFFAOYSA-N 2h-benzotriazole;carbonic acid Chemical compound OC(O)=O.C1=CC=C2NN=NC2=C1 BTBWSRPRAGXJJV-UHFFFAOYSA-N 0.000 description 1
IHDBZCJYSHDCKF-UHFFFAOYSA-N 4,6-dichlorotriazine Chemical compound ClC1=CC(Cl)=NN=N1 IHDBZCJYSHDCKF-UHFFFAOYSA-N 0.000 description 1
QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 description 1
WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010059378 Endopeptidases Proteins 0.000 description 1
102000005593 Endopeptidases Human genes 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010015719 Exsanguination Diseases 0.000 description 1
108010061932 Factor VIIIa Proteins 0.000 description 1
108090001126 Furin Proteins 0.000 description 1
102000004961 Furin Human genes 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
206010018852 Haematoma Diseases 0.000 description 1
206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
101000823435 Homo sapiens Coagulation factor IX Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000192130 Leuconostoc mesenteroides Species 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
206010061298 Mucosal haemorrhage Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 1
108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
229920001734 PEG propionaldehyde Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
206010038980 Retroperitoneal haemorrhage Diseases 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
241000194019 Streptococcus mutans Species 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
229930003448 Vitamin K Natural products 0.000 description 1
102100038182 Vitamin K-dependent gamma-carboxylase Human genes 0.000 description 1
DAJVWAYAPWDUTO-UHFFFAOYSA-N [2-(hydroxymethyl)-3-phosphonooxy-5-(3-tetradecanoyloxytetradecanoylamino)oxan-4-yl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(CCCCCCCCCCC)CC(=O)NC1COC(CO)C(OP(O)(O)=O)C1OC(=O)CCCCCCCCCCCCC DAJVWAYAPWDUTO-UHFFFAOYSA-N 0.000 description 1
YQKFJYBRZVNXKQ-UHFFFAOYSA-N [Na].BC#N Chemical compound [Na].BC#N YQKFJYBRZVNXKQ-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
102000004139 alpha-Amylases Human genes 0.000 description 1
108090000637 alpha-Amylases Proteins 0.000 description 1
229940024171 alpha-amylase Drugs 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000013103 analytical ultracentrifugation Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
DSEORJACOQDMQX-UHFFFAOYSA-N bis(2,3,4-trichlorophenyl) carbonate Chemical compound ClC1=C(Cl)C(Cl)=CC=C1OC(=O)OC1=CC=C(Cl)C(Cl)=C1Cl DSEORJACOQDMQX-UHFFFAOYSA-N 0.000 description 1
ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229960001714 calcium phosphate Drugs 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
108090001015 cancer procoagulant Proteins 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
238000012511 carbohydrate analysis Methods 0.000 description 1
229940077731 carbohydrate nutrients Drugs 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000002983 circular dichroism Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000001609 comparable effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000005138 cryopreservation Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
208000001780 epistaxis Diseases 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000727 fraction Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000006251 gamma-carboxylation Effects 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
108010013113 glutamyl carboxylase Proteins 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
108010085617 glycopeptide alpha-N-acetylgalactosaminidase Proteins 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
210000002288 golgi apparatus Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000010005 growth-factor like effect Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
208000002085 hemarthrosis Diseases 0.000 description 1
208000006750 hematuria Diseases 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229940052349 human coagulation factor ix Drugs 0.000 description 1
235000020256 human milk Nutrition 0.000 description 1
210000004251 human milk Anatomy 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000035777 life prolongation Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical group 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229940092110 macugen Drugs 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
229940071846 neulasta Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
238000010915 one-step procedure Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940002988 pegasys Drugs 0.000 description 1
108010044644 pegfilgrastim Proteins 0.000 description 1
108010092853 peginterferon alfa-2a Proteins 0.000 description 1
108010092851 peginterferon alfa-2b Proteins 0.000 description 1
229940106366 pegintron Drugs 0.000 description 1
LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
229940070376 protein Drugs 0.000 description 1
108010012557 prothrombin complex concentrates Proteins 0.000 description 1
239000002994 raw material Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
239000004627 regenerated cellulose Substances 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
210000003660 reticulum Anatomy 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
125000005630 sialyl group Chemical group 0.000 description 1
230000009450 sialylation Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
229910000342 sodium bisulfate Inorganic materials 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
150000003721 vitamin K derivatives Chemical class 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
229940046010 vitamin k Drugs 0.000 description 1
239000011800 void material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

CA2709960A 2007-12-27 2008-12-19 Chemically modified factor ix Abandoned CA2709960A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US926307P	2007-12-27	2007-12-27
US61/009,263		2007-12-27
PCT/EP2008/010925 WO2009083187A1 (en)	2007-12-27	2008-12-19	Chemically modified factor ix

Publications (1)

Publication Number	Publication Date
CA2709960A1 true CA2709960A1 (en)	2009-07-09

Family

ID=40344940

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2709960A Abandoned CA2709960A1 (en)	2007-12-27	2008-12-19	Chemically modified factor ix

Country Status (11)

Country	Link
US (2)	US20090176708A1 (ja)
EP (4)	EP2568041A1 (ja)
JP (1)	JP2011507919A (ja)
KR (1)	KR20100110799A (ja)
CN (1)	CN101952422A (ja)
AU (1)	AU2008342260B2 (ja)
CA (1)	CA2709960A1 (ja)
IL (1)	IL206095A0 (ja)
NZ (3)	NZ603997A (ja)
RU (1)	RU2010131189A (ja)
WO (1)	WO2009083187A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2353588B1 (en)	2010-01-21	2015-04-15	Agricultural Technology Research Institute	A sustained release preparation of factor IX
UY35463A (es)	2013-03-15	2014-10-31	Biogen Idec Inc	Formulaciones de polipéptido fc-factor ix.
AR099340A1 (es) *	2014-02-12	2016-07-13	Novo Nordisk As	Conjugados del factor de coagulación ix
KR102385372B1 (ko)	2014-03-24	2022-04-11	바이오버라티브 테라퓨틱스 인크.	동결건조된 ix 인자 제형
US20220378840A1 (en) *	2019-11-29	2022-12-01	Rutgers, The State University Of New Jersey	Compositions, kits and methods for storage of blood products and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS538750B2 (ja)	1971-08-18	1978-03-31
AT348548B (de)	1977-04-08	1979-02-26	Laevosan Gmbh & Co Kg	Verfahren zur herstellung von alsblutplasma- expander geeignerter hydroxyaethylstaerke
US5614500A (en) *	1983-03-04	1997-03-25	The Scripps Research Institute	Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
DE3313600A1 (de)	1983-04-14	1984-10-18	Laevosan-Gesellschaft mbH & Co. KG, Linz	Plasmastreckmittel auf staerkebasis und verfahren zu ihrer herstellung
DE3919729C3 (de) *	1989-06-16	1997-06-19	Fresenius Ag	Hydroxyethylstärke als Plasmaexpander, Verfahren zu ihrer Herstellung und Verwendung als kolloidales Plasmaersatzmittel
FR2702160B1 (fr)	1993-03-02	1995-06-02	Biovecteurs As	Vecteurs particulaires synthétiques et procédé de préparation.
DE4310974C2 (de)	1993-04-03	1996-08-01	Fresenius Ag	Verwendung von Hydroxyethylstärke zur Verbesserung der Mikrozirkulation
FR2704145B1 (fr)	1993-04-21	1995-07-21	Pasteur Institut	Vecteur particulaire et composition pharmaceutique le contenant.
US5621039A (en) *	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
FR2723849B1 (fr)	1994-08-31	1997-04-11	Biovector Therapeutics Sa	Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
ES2160410T3 (es) *	1997-04-08	2001-11-01	Baxter Ag	Preparados de complejos de protrombina inmunotolerantes.
US7179617B2 (en) *	2001-10-10	2007-02-20	Neose Technologies, Inc.	Factor IX: remolding and glycoconjugation of Factor IX
WO2004089280A2 (en)	2003-04-08	2004-10-21	Yeda Research And Development Co. Ltd.	Reversible pegylated drugs
WO2005014655A2 (en) *	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
US20060040856A1 (en) *	2003-12-03	2006-02-23	Neose Technologies, Inc.	Glycopegylated factor IX
AU2004296860B2 (en) *	2003-12-03	2010-04-22	Novo Nordisk A/S	Glycopegylated factor IX
ZA200608126B (en)	2004-03-01	2008-02-27	Braun Melsungen Ag	Hydroxyethyl starch
EP2336192A1 (en) *	2004-03-11	2011-06-22	Fresenius Kabi Deutschland GmbH	Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
BRPI0514396A2 (pt) *	2004-08-17	2009-05-12	Csl Behring Gmbh	polipeptìdeos dependentes de vitamina k modificada
CN101137396A (zh) *	2005-03-11	2008-03-05	弗雷泽纽斯卡比德国有限公司	由无活性初始材料制备生物活性糖蛋白
EP1991257B1 (en) *	2006-03-07	2015-05-06	Baxter International Inc.	Highly phosphorylated and sulfated recombinant factor ix
CN101454267B (zh)	2006-03-29	2012-09-26	帝斯曼知识产权资产管理有限公司	姜黄素的合成
EP2084274A2 (en) *	2006-06-19	2009-08-05	Nautilus Technology LLC	Modified coagulation factor ix polypeptides and use thereof for treatment

2008
- 2008-12-19 NZ NZ603997A patent/NZ603997A/xx not_active IP Right Cessation
- 2008-12-19 US US12/339,619 patent/US20090176708A1/en not_active Abandoned
- 2008-12-19 KR KR1020107014071A patent/KR20100110799A/ko not_active Application Discontinuation
- 2008-12-19 CA CA2709960A patent/CA2709960A1/en not_active Abandoned
- 2008-12-19 AU AU2008342260A patent/AU2008342260B2/en not_active Expired - Fee Related
- 2008-12-19 EP EP12008214A patent/EP2568041A1/en not_active Withdrawn
- 2008-12-19 EP EP12008216A patent/EP2568043A1/en not_active Withdrawn
- 2008-12-19 RU RU2010131189/10A patent/RU2010131189A/ru not_active Application Discontinuation
- 2008-12-19 NZ NZ585835A patent/NZ585835A/en not_active IP Right Cessation
- 2008-12-19 NZ NZ598193A patent/NZ598193A/xx not_active IP Right Cessation
- 2008-12-19 JP JP2010540056A patent/JP2011507919A/ja active Pending
- 2008-12-19 EP EP08868384A patent/EP2247723A1/en not_active Withdrawn
- 2008-12-19 WO PCT/EP2008/010925 patent/WO2009083187A1/en active Application Filing
- 2008-12-19 CN CN2008801232530A patent/CN101952422A/zh active Pending
- 2008-12-19 EP EP12008215A patent/EP2568042A1/en not_active Withdrawn
2010
- 2010-05-31 IL IL206095A patent/IL206095A0/en unknown
2011
- 2011-12-29 US US13/339,823 patent/US20120177625A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL206095A0 (en)	2010-11-30
US20090176708A1 (en)	2009-07-09
NZ585835A (en)	2012-07-27
US20120177625A1 (en)	2012-07-12
WO2009083187A1 (en)	2009-07-09
JP2011507919A (ja)	2011-03-10
CN101952422A (zh)	2011-01-19
WO2009083187A8 (en)	2009-09-17
EP2568043A1 (en)	2013-03-13
EP2568041A1 (en)	2013-03-13
KR20100110799A (ko)	2010-10-13
EP2568042A1 (en)	2013-03-13
RU2010131189A (ru)	2012-02-10
EP2247723A1 (en)	2010-11-10
AU2008342260B2 (en)	2013-10-17
AU2008342260A1 (en)	2009-07-09
NZ603997A (en)	2013-02-22
NZ598193A (en)	2012-12-21

Legal Events

Date	Code	Title	Description
2012-10-25	EEER	Examination request
2015-02-15	FZDE	Discontinued	Effective date: 20141219

Publication	Publication Date	Title
US10251941B2 (en)	2019-04-09	Factor VIIa-polysialic acid conjugates having prolonged in vivo half-life
US9458444B2 (en)	2016-10-04	Long-acting coagulation factors and methods of producing same
KR101273229B1 (ko)	2013-06-11	변형된 활성화 특성을 갖는 응고 인자 ｘ 폴리펩타이드
US8759292B2 (en)	2014-06-24	Long-acting coagulation factors and methods of producing same
AU2016202829B2 (en)	2017-05-25	Long-acting coagulation factors and methods of producing same
US20200255816A1 (en)	2020-08-13	Long-acting coagulation factors and methods of producing same
KR20080107385A (ko)	2008-12-10	변형된 활성화 특성을 갖는 응고 인자 ｘ 폴리펩타이드
SG178141A1 (en)	2012-03-29	Blood coagulation protein conjugates
EP3988113A1 (en)	2022-04-27	Long-acting coagulation factors and methods of producing same
US20150079063A1 (en)	2015-03-19	Long-acting coagulation factors and methods of producing same
US20120177625A1 (en)	2012-07-12	Chemically modified factor ix